FLX475 in Combination With Ipilimumab in Advanced Melanoma

Part of paid clinical trials in Los Angeles, California.

Sponsor
RAPT Therapeutics, Inc.
Study ID
NCT04894994
Phase
PHASE2
Status
Terminated

Conditions

  • Advanced Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • FLX475 — DRUG
    Tablet
  • Ipilimumab — DRUG
    IV infusion

Study Details

This clinical trial is a Phase 2, open-label study to determine the anti-tumor activity of FLX475 in combination with ipilimumab in subjects with advanced melanoma previously treated with an anti-programmed cell death 1 (anti-PD-1) or anti-programmed cell death ligand 1 (anti-PD-L1) agent. The study will be conducted starting with a safety run-in portion in which 6 eligible subjects will be enrolled and treated for at least one 3-week cycle to determine if the safety profile of FLX475+ipilimumab is acceptable to complete enrollment of the approximately 20-subject study.

Key Dates

Start date
Sep 3, 2021
Status verified
Dec 2023
Primary completion
Sep 13, 2022
Completion
Sep 13, 2022

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: FLX475 and ipilimumab combination therapy
    Participants received FLX475 tablets orally and ipilimumab by IV infusions

Primary Outcome Measure

Objective Response Rate [ Time Frame: Approximately 1 year ]

Locations (4)

FacilityCityStateZIPSite coordinators
University of California, Los AngelesLos AngelesCalifornia90095-
Moffitt Cancer CenterTampaFlorida33612-
Washington University School of Medicine St. LouisSt LouisMissouri63110-
The University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Los Angeles, CA

By research site
University of California, Los Angeles· Los Angeles, CAMoffitt Cancer Center· Tampa, FLWashington University School of Medicine St. Louis· St Louis, MOThe University of Texas MD Anderson Cancer Center· Houston, TX

Related Studies